Market: NASD |
Currency: USD
Address: 1040 West Georgia Street
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
📈 Achieve Life Sciences, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$15.50
-
Upside/Downside from Analyst Target:
368.28%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-06
-
EPS Estimate:
-0.26
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2020 |
- |
$0.050000 |
- |
2020-07-31 |
- |
Stock split |
|
Total Amount for 2020: $0.050000 |
| 2018 |
- |
$0.100000 |
- |
2018-05-24 |
- |
Stock split |
|
Total Amount for 2018: $0.100000 |
| 2017 |
- |
$0.090909 |
- |
2017-08-03 |
- |
Stock split |
|
Total Amount for 2017: $0.090909 |
📅 Earnings & EPS History for Achieve Life Sciences, Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-07 | -0.37 |
| 2025-05-13 | -0.37 |
| 2025-03-11 | -0.36 |
| 2024-11-07 | -0.36 |
| 2024-08-13 | -0.25 |
| 2024-05-09 | -0.26 |
| 2024-03-28 | -0.26 |
| 2023-11-09 | -0.34 |
| 2023-08-14 | -0.43 |
| 2023-05-09 | -0.5 |
| 2023-03-16 | -0.83 |
| 2022-11-14 | -1.35 |
| 2022-08-11 | -1.08 |
| 2022-05-12 | -0.8 |
| 2022-03-10 | -0.76 |
| 2021-11-09 | -0.71 |
| 2021-08-12 | -1.53 |
| 2021-05-13 | -1.3 |
| 2021-03-11 | -1.11 |
| 2020-11-12 | -1.14 |
| 2020-08-06 | -1.68 |
| 2020-05-14 | -2.2 |
| 2020-03-13 | -6 |
| 2019-11-06 | -9 |
📰 Related News & Research
No related articles found for "achieve life".
